Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSE: Secukinumab QoL in Psoriasis
NCT02752776Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoint: Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at 16 weeks. Started Mar 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02752776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752776.